Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms and a Phase 1 Combination Therapy arm Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B). Phase 2 Monotherapy is a randomized, open-label, crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidine. Phase 3 Monotherapy is a randomized open-label crossover study comparing the final fixed dose of oral ASTX030 to SC azacitidine. Phase 1 Combination Therapy is an open-label, multicenter, randomized, exploratory study comparing ASTX030 and SC azacitidine in combination with venetoclax in participants with AML.
The duration of this multi-phase study is approximately 7 years.
Full description
The Phase 1 and Phase 2 Monotherapy arms have completed enrolment. The Phase 3 Monotherapy and Phase 1 Combination Therapy arms are open for enrolment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Phase 2 Monotherapy:
Phase 3 Monotherapy:
Has confirmed MDS or CMML and is a candidate to receive and benefit from single agent azacitidine as applicable according to local country approvals and/or local institution standard practice:
a) French-American-British myelodysplastic syndrome subtypes: refractory anemia (RA) or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and CMML or MDS with intermediate-2 or high risk MDS according to the International Prognostic Scoring System (IPSS).
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Participants with adequate organ function.
For participants with prior allogeneic stem cell transplant, no evidence of graft-versus-host disease (GVHD).
Participants with no major surgery within 3 weeks before first study treatment.
Participants with no cytotoxic chemotherapy (excluding hydroxyurea) within 4 weeks before first study treatment.
Is able to swallow the number of tablets/capsules required for the treatment assignment within a 10-minute period and tolerate 4 hours of fasting.
Participants with projected life expectancy of at least 12 weeks.
Phase 1 Combination Therapy:
Has histological confirmation of newly diagnosed AML by World Health Organization (WHO) 2022 criteria.
Participants with projected life expectancy of at least 12 weeks.
Must be considered ineligible for intensive induction chemotherapy defined by the following:
a. Aged 75 years or older, or b. Aged 18 to 74 years with at least one of the following comorbidities: i. Severe cardiac disorder (e.g., congestive heart failure requiring treatment, ejection fraction ≤50%, or chronic stable angina).
ii. Severe pulmonary disorder (e.g., diffusing capacity of the lung for carbon monoxide (DLCO) ≤65% or forced expiratory volume in 1 second [FEV1] ≤65%). iii. Creatinine clearance ≥30 mL/min to <45 mL/min. iv. Moderate hepatic impairment with total bilirubin >1.5 to ≤3.0 × upper limit of normal (ULN).
v. ECOG Performance Status of 2 or 3.
Has an ECOG Performance Status of 0-2 for participants ≥75 years of age or 0-3 for participants 18 to 74 years of age.
Exclusion criteria
All Monotherapy Phases:
Phase 1 Combination Therapy:
Has a history of MPN including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia with or without BCR-ABL1 translocation, or AML with BCR-ABL1 translocation.
Has the following karyotype abnormalities: t(15;17) or other acute promyelocytic leukemia variants that remain sensitive to all-trans retinoic acid (ATRA) therapy.
Has known active central nervous system involvement from AML.
Has known human immunodeficiency virus (HIV) infection.
Is known to be positive for Hepatitis B or C infection.
Has severe hepatic impairment
Has severe renal impairment
Has a malabsorption syndrome or other condition that precludes enteral route of administration.
Has a cardiovascular disability status of New York Heart Association Class >2.
Has significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular, or pulmonary disease; or any other medical condition that in the opinion of the investigator would adversely affect his/her participation in this study.
Has clinically significant uncontrolled systemic infection requiring therapy (viral, bacterial, or fungal).
Has a history of other malignancies prior to study entry with the exception of adequately treated in situ carcinoma of the breast or cervix uteri; localized basal cell carcinoma or squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or adequately treated and controlled with other modalities); and any early stage malignancy for which no definitive therapy is required.
Has a WBC count >25,000/ microliters (μL) (hydroxyurea treatment is permitted to meet this criterion).
Has received treatment with any of the following:
Cannot discontinue treatment with any of the following:
Cannot avoid concomitant drugs known as moderate or strong CYP3A inducers.
Cannot discontinue treatment with any drugs that delay gastric emptying such as GLP-1 and/or GIP agonists in Cycles 1 and 2 of the study.
Is participating in another research study requiring interventions such as drug therapy or study procedures.
Has a known or suspected hypersensitivity to cedazuridine, azacitidine, venetoclax, or any of their excipients.
Has known significant mental illness or other conditions such as alcohol or other substance abuse or addictions
Consumes grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or starfruit ≤7 days prior to C1D1.
Primary purpose
Allocation
Interventional model
Masking
236 participants in 5 patient groups
Loading...
Central trial contact
Taiho Oncology, Inc.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal